BMS309403

Catalog No.S6622 Batch:S662201

Print

Technical Data

Formula

C31H26N2O3
Molecular Weight 474.55 CAS No. 300657-03-8
Solubility (25°C)* In vitro DMSO 95 mg/mL (200.18 mM)
Ethanol 18 mg/mL (37.93 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description BMS309403 is a small-molecule FABP4 inhibitor with nM affinity (Kd=4 nM for FABP4) and >100-fold selectivity against FABP5 as well as the heart isoform FABP3.
Targets
FABP4 [1]
(Cell-free assay)
4 nM(Kd)
In vitro

Treatment of BMS309403 (FABP4 inhibitor) comobined with SSO (CD36 inhibitor) significantly decreases the breast cancer cell viability, proliferative, migratory, and invasive abilities over 72 h. Inhibiting either at recommended concentrations does not significantly decrease the breast cancer cell viability over 72 h. Treatment with both SSO and BMS309403 results in clustering of cells and increased lipid content, indicating an inability to metabolise lipids resulting potentially in lipotoxicity-induced apoptosis.[1]
In vivo

Treatment with either BMS309403 or SSO alone decreases the rate of tumour formation and the combination of BMS309403 and SSO significantly decreased the rate of tumour formation.

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    Humen breast cancer cell lines

  • Concentrations

    20 μM

  • Incubation Time

    72 h

  • Method

    Cell viability after CD36 knockout or treatment with SSO and BMS-309403 is determined by seeding 2500 cells in 96-well plate, and cultured for 24 h, after which treatment agent is added at appropriate concentration and maintained for 72 h. Cell viabilities is evaluated at 6, 12, 24, 36, 48, 60 and 72 h using the EZ-CYTOX cell viability kit.

Selleck's BMS309403 has been cited by 3 publications

Fatty acid-binding protein 4 is a therapeutic target for septic acute kidney injury by regulating inflammatory response and cell apoptosis [ Cell Death Dis, 2022, 13(4):333] PubMed: 35410456
FABP4-mediated lipid droplet formation in Streptococcus uberis-infected macrophages supports host defence [ Vet Res, 2022, 53(1):90] PubMed: 36371263
Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer [ NPJ Breast Cancer, 2021, 7(1):129] PubMed: 34561446

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.